well-posit growth amid
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
target larg potenti market opportun
nation heart blood lung institut estim
million american suffer sleep apnoea accord
fewer million diagnos
treat sleep apnoea year expand pool
diagnos treat sleep apnoea patient compani
target disord much gain
strategi involv increas awar disord
among physician gener popul compani
also make test sleep apnoea simpler home
test devic expand compani reach
patient unwil treat sleep lab
importantli aim introduc new devic
make patient comfort compliant
treatment provid compani stream
recur revenu
oan age popul coupl acceler obes
trend drive signific growth
steadi rate innov differenti
advantag histor support premium
omount evid clinic relev sleep
condit --
hypertens diabet -- increas demand
medic
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
develop manufactur distribut medic devic --
airflow gener mask -- treat breath disord also market
ventil product sleep apnoea remain compani primari
focu reach truli global distribut capabl
countri wholli own independ firm
increas proport manufactur capac singapor
still australia compani found
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
deliv solid
return long
innov
busi strategi outlook oct
remain one key leader sleep apnoea
treatment expect compani deliv solid return
long run underpin innov capabl
focus develop medic devic treat
sleep apnoea respiratori problem
educ caregiv therapi option firm
product portfolio consist airflow gener nasal
mask pillow introduc airflow need
prop open patient respiratori pathway sleep
tool help patient breath easier avoid
complic associ sleep apnoea includ
exhaust hypertens gener half
sale half sale
throughout europ japan
second mover sleep apnoea devic
initi forc play catch-up differenti
technic superior devic still aim maintain
technic edg serv well far patient
difficult time adjust sleep disrupt
advanc featur lead greater patient
comfort complianc turn lead brand loyalti
patient return sleep lab home
mask pillow -- highli profit recur revenu
stream help endear custom base
product launch continu impress
innov success combat price eros
prevent declin return capit
think prove abil develop new
sleep apnoea treatment expect
futur consid develop capabl
larg potenti patient pool remain
undiagnos untreat sleep apnoea market
look posit continu grow fast
clip fill gap exist therapeut option
fair valu estim stand aud
per australian chess depositari interest cdi
calcul use australian dollar/u dollar exchang
rate adjust ratio cdi/primari
stock assign firm cost equiti littl
debt weight averag cost capit
five year fiscal expect key
demograph trend increas penetr
potenti patient pool greater awar
conveni test option drive compound annual
sale growth firm expect competit
environ five-year period limit scale
economi firm increas market spend
nevertheless forecast oper leverag drive
annual growth oper incom period
face tough competit though particularli
philip formerli respiron respiron pioneer
industri possess admir market
distribut capabl accordingli product
becom synonym sleep apnoea treatment
 face difficult challeng tri
educ physician product set competitor
also shown willing compet price
blanket market free sampl past new
compani reach patient expect
educ home test initi
firm profit expand faster base forecast
either better oper effici stronger
dollar/australian dollar translat consid
rais fair valu estim aud per cdi
scenario assum sale increas
compound annual basi next five year effect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
sleep apnoea
breath increas awar sleep apnoea
particular despit sign increas competit mask
low-tech end flow gener believ
integr product suit creat applic
switch cost clinician patient key aspect
latest product offer built-in wireless
connect togeth on-line data informat
manag tool clinician bode well patient
treatment efficaci
view moat trend stabl
philip effect duopoli domin
market sleep apnoea devic decad
absenc potenti disruptor horizon
see chang time soon proven
abil innov market healthcar stakehold
think firm remain leader market
forese futur expect momentum new
product develop maintain given on-going
research develop spend revenu
demand product deceler result
competit threat margin contract either
oper ineffici weaker dollar
consid lower fair valu estim aud
per cdi scenario assum sale increas
compound annual basi next five
assign narrow moat rate base
intang asset switch cost given strong track
record innov product introduct coupl
solid patent posit dug narrow econom
moat around busi develop
market capabl sleep apnoea devic new
product launch core sleep apnoea busi
grow portfolio respiratori product focus copd
neuromuscular diseas cardio-respiratori condit
underpin posit stanc compani strong
competit posit market educ
effort rais clinic profil sleep-disord
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
target larg under-penetrated sleep-
disord breath market growth continu
strong trajectori patient incorpor
non-invasive treatment sleep
owith focu shift toward complianc rather
low-cost system thrive given
histori introduc innov product
oa signific boost at-hom sleep apnoea test
could open market patient object
costli uncomfort test sleep lab
abil sell product depend larg
willing third parti pay treatment
lower reimburs rate product
would hurt revenu margin potenti
research
develop unabl introduc new product
marketplac success sale margin
ocompetit sampl hurt growth recent
year practic return attract
sleep apnoea devic market could diminish
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
nearli usd million cash cash equival
june compar usd million total
debt remain excel financi health given
abil gener signific free cash flow expect
posit strengthen futur year
like medical-devic firm must innov
face signific price pressur compani may
abl stay head innov class futur
year would creat open competitor
compani also face foreign exchang risk substanti
develop manufactur oper remain
australia firm found
sale dispers throughout rest
world account half sale
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
mick farrel posit sinc
son founder peter farrel compani
execut chairman strong free cash flow
gener intern fund growth mani
year issu fresh equiti employ
rel littl debt return invest capit
consist well cost capit
upward trend recent year major growth
follow three major contributor effect invest
research develop maintain leadership
invest clinic trial demonstr medic
benefit treat condit distribut expertis
reach
sleep-disord breath
acquisit strategi buy rel small
firm complementari technolog intellectu
properti seen manag risk materi
amount capit acquisit found
value-destruct
repres date owner name posit common share held report holder issuer
bae system employe save invest
america pension
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
resm breez share appear fulli valu
narrow-moat deliv strong final quarter
solid growth front geographi despit fall
slightli short expect full year non-gaap
net incom usd million group revenu usd
billion respect year year
compar forecast usd million usd
billion nonetheless mask sale impress grow
around constant currenc fourth quarter
market rate full year unit state
rest world benefit continu strong
demand airfit full-fac mask airfit
nasal mask devic also perform strongli end year
year year constant currenc term
follow result rais fair valu estim
usd per share usd previous
adjust guidanc research develop
cost percentag group revenu time valu
money factor expect contribut
recent healthcarefirst acquisit fiscal forecast
specif reduc cost group
revenu previous revis fair valu
estim equat aud per cdi base
australian dollar/u dollar exchang rate
aud per cdi previous consid share
current level fulli valu
think cloud-connect suit product
remain well-posit compet develop market
given valu proposit patient clinician
clinic outcom reduc cost associ medic
condit healthcar payor expect
continu double-digit growth mask sale support
follow initi first resuppli program
home medic equip supplier essenti remind
end custom replac worn mask time basi
benefit
brightre patient
manag offer hospic homecar set
enhanc recent healthcarefirst bolt-on
use full-fac mask third favour
chang reimburs franc japan south
recent studi cite manag peg global
preval peopl mild moder sever sleep
apnoea around million estim
penetr around coupl grow
awar sleep apnoea associ medic
condit expect double-digit growth continu
remain comfort forecast global mask sale
grow five-year annual compound-annual-growth-rate compar
five-year sale compound-annual-growth-rate devic
unchang gross margin improv slightli
fiscal fiscal reflect
typic declin averag sell price off-set
manufactur procur effici
includ impact currenc movement remain
signific variabl top line cost line
balanc sheet remain solid usd million
cash hand well support on-going strong cash
flow oper impress cash flow
oper fiscal grew usd million
report debt/adjust ebitda period end
around time compar around time
fiscal follow sizabl usd million acquisit
brightre remain comfort
manag abil support dividend pay-out
ratio around also fund strateg
acquisit cloud-en softwar provid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
momentum continu resm unveil multipl
product initi new mask technolog apr
deliv anoth solid quarter net incom
usd million group revenu usd million
year-ago third quarter
respect oper leverag major factor
sell gener administr expens
lesser degre research develop cost trend
sequenti basi also unveil sever
launch new
smartphon app screen sleep apnoea china
launch resmed-brand portabl oxygen
concentr mobi unit state follow
result rais fair valu estim narrow-
moat usd per share usd
updat oper expens assumpt incorpor
tax guidanc fiscal fiscal equat
aud per depositari interest base
australian dollar/u dollar exchang rate
aud per cdi previous consid share
current level line fair valu
includ
sleep apnoea
technolog key sourc narrow moat rate remain
intact continu benefit airsens
platform launch quarterli sale growth
third quarter robust despit cycl strong
prior correspond period across product categori
geographi expect new product initi
launch mobi roll-out new quiet
air diffus technolog quietair full-fac mask
reimburs franc japan south korea
maintain posit momentum medium term
conjunct
maintain five-year revenu compound annual
growth rate forecast devic mask
respect versu broader market growth
third quarter devic mask sale reach
usd million usd million increas
respect year year europ asia
market impress devic mask sale usd
million usd million respect
constant currenc term buoy stronger euro gross
margin group remain stabl around
quarter consist prior correspond period
resm balanc sheet solid flow gener
remain strong support cash flow oper year
date usd million year year net debt
around usd million end march
year year forecast end fiscal
net cash posit compar net debt/ebitda
fiscal oper leverag gain past
three quarter seen sell gener administr
expens percentag group revenu trend
stabil
lower forecast sg
assumpt also lower research
develop cost assumpt slightli
incorpor guidanc
compani declar quarterli dividend usd per
share repres pay-out ratio given
strength earn modest level gear remain
comfort abil fund sharehold
manag also provid updat australian
taxat offic audit year deliv
march assert compani owe usd
million addit incom tax usd million
accru interest contest transfer price
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
issu pursu administr legal action
nonetheless compani agre pay
assess record liabil third quarter
pend resolut matter stage
use effect tax guidanc provid manag
fiscal revert fiscal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end june
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
